Financial Impact of Treatment Choice in Chronic Myeloid Leukemia: A Comparison of Later Generation TKIs versus Imatinib from Patient and Payer Perspectives
ClinicoEconomics and Outcomes Research · 2026-07 · Volume 18 · 1-12
DOI: 10.2147/ceor.s626752 ↗Kurz gefasst
Fachartikel in der Zeitschrift ClinicoEconomics and Outcomes Research, 2026-07. Verfasst von Jennifer E Vaughn und 5 weiteren Autor:innen. Beteiligte Einrichtung: James Cancer Hospital and Solove Research Institute, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- James Cancer Hospital and Solove Research Institute, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
- Center for Healthcare Economics and Policy, FTI Consulting, Los Angeles, CA, USA.
- Center for Healthcare Economics and Policy, FTI Consulting, Washington, DC, USA.
- Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
ORCID-Profile: Jason Shafrin
Zitieren
APA
Vaughn, J. E., Zawadzki, N., Zhang, S., Pinkston, P., Wei, D., & Shafrin, J. (2026). Financial Impact of Treatment Choice in Chronic Myeloid Leukemia: A Comparison of Later Generation TKIs versus Imatinib from Patient and Payer Perspectives. ClinicoEconomics and Outcomes Research, Volume 18, 1-12. https://doi.org/10.2147/ceor.s626752
Vancouver
Vaughn JE, Zawadzki N, Zhang S, Pinkston P, Wei D, Shafrin J. Financial Impact of Treatment Choice in Chronic Myeloid Leukemia: A Comparison of Later Generation TKIs versus Imatinib from Patient and Payer Perspectives. ClinicoEconomics and Outcomes Research. 2026;Volume 18:1-12. doi:10.2147/ceor.s626752
BibTeX
@article{Vaughn2026,
author = {Vaughn, Jennifer E and Zawadzki, Nadine and Zhang, Shurui and Pinkston, Paul and Wei, David and Shafrin, Jason},
title = {Financial Impact of Treatment Choice in Chronic Myeloid Leukemia: A Comparison of Later Generation TKIs versus Imatinib from Patient and Payer Perspectives},
journal = {ClinicoEconomics and Outcomes Research},
year = {2026},
volume = {Volume 18},
pages = {1--12},
doi = {10.2147/ceor.s626752}
}
EUVIMED